Valuation: Illumina, Inc.

Capitalization 21.56B 18.3B 16.76B 15.8B 29.47B 2,054B 29.71B 199B 77.57B 978B 80.9B 79.2B 3,386B P/E ratio 2026 *
30.1x
P/E ratio 2027 * 25.3x
Enterprise value 21.91B 18.59B 17.03B 16.06B 29.95B 2,088B 30.19B 202B 78.82B 994B 82.21B 80.48B 3,441B EV / Sales 2026 *
4.8x
EV / Sales 2027 * 4.39x
Free-Float
75.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week+2.25%
Current month+12.44%
1 month+17.85%
3 months+22.45%
6 months+16.24%
Current year+8.65%
1 week 134.67
Extreme 134.67
145.21
1 month 119.14
Extreme 119.14
145.21
Current year 112.65
Extreme 112.65
155.53
1 year 77.5
Extreme 77.5
155.53
3 years 68.7
Extreme 68.7
213.91
5 years 68.7
Extreme 68.7
526
10 years 68.7
Extreme 68.7
555.77
Manager TitleAgeSince
Chief Executive Officer 51 25/09/2023
Director of Finance/CFO 50 15/04/2024
Chief Tech/Sci/R&D Officer 55 29/05/2025
Director TitleAgeSince
Director/Board Member 71 29/11/2012
Director/Board Member 70 28/01/2016
Director/Board Member 65 28/07/2016
Change 5d. change 1-year change 3-years change Capi.($)
+0.44%+2.25%+88.11%-31.55% 21.56B
-2.67%-2.16%+12.27%-14.57% 168B
-6.67%-7.14%-21.71%+38.42% 149B
-2.71%-4.32%-12.23%-27.85% 118B
-1.04%-6.12%-48.11%-0.04% 79.33B
-3.49%-7.39%+4.74%-13.08% 44.43B
+1.13%-4.49%-31.09%-37.46% 44.14B
-1.99%+15.30%+1.17%+29.41% 34.17B
-3.60%-0.64%+4.24%-12.69% 31.5B
-0.82%+0.48%-24.46%-44.35% 30.12B
Average -1.43%-0.72%-2.71%-11.38% 72.01B
Weighted average by Cap. -1.49%-2.70%-8.68%-5.09%

Financials

2026 *2027 *
Net sales 4.57B 3.88B 3.55B 3.35B 6.24B 435B 6.29B 42.09B 16.43B 207B 17.14B 16.78B 717B 4.82B 4.09B 3.75B 3.53B 6.59B 459B 6.64B 44.44B 17.35B 219B 18.09B 17.71B 757B
Net income 727M 617M 565M 532M 993M 69.22B 1B 6.7B 2.61B 32.97B 2.73B 2.67B 114B 857M 728M 666M 628M 1.17B 81.68B 1.18B 7.9B 3.08B 38.9B 3.22B 3.15B 135B
Net Debt 349M 296M 271M 256M 477M 33.26B 481M 3.22B 1.26B 15.84B 1.31B 1.28B 54.82B -377M -320M -293M -277M -516M -35.95B -520M -3.48B -1.36B -17.12B -1.42B -1.39B -59.25B
Logo Illumina, Inc.
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Employees
8,625
Date Price Change Volume
11/05/26 142.51 $ +0.44% 2,063,652
08/05/26 141.88 $ +2.29% 1,499,702
07/05/26 138.71 $ -2.71% 1,241,144
06/05/26 142.58 $ +2.52% 1,332,062
05/05/26 139.07 $ -0.22% 1,236,498
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
142.51USD
Average target price
140.67USD
Spread / Average Target
-1.29%

Quarterly revenue - Rate of surprise